SALT LAKE CITY, May 22, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN - News) announced today that the Company is scheduled to present at two upcoming investor conferences: <\/p>\n
Both presentations will be available to interested parties via webcast on the investor relations section of Myriad's website at http:\/\/www.myriad.com<\/a>. <\/p>\n About Myriad Genetics <\/p>\n Myriad Genetics, Inc. is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease. Myriad is working on strategic directives, including new product introductions, companion diagnostics, and international expansion, to take advantage of significant growth opportunities. For more information on how Myriad is making a difference, please visit the Company's website: http:\/\/www.myriad.com<\/a>. <\/p>\n<\/p>\n See the original post:<\/p>\n Myriad Genetics to Present at Upcoming Investor Conferences in June<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" SALT LAKE CITY, May 22, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN - News) announced today that the Company is scheduled to present at two upcoming investor conferences: Both presentations will be available to interested parties via webcast on the investor relations section of Myriad's website at http:\/\/www.myriad.com<\/a>. Continue reading